NCT00500266View on ClinicalTrials.gov

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

1,053

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

May 31, 2009

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine (13vPnC)

Trial Locations (59)

10717

Berlin

Berlin-Wilmersdorf

10969

Berlin

11136

Stockholm

13031

Camillus

14059

Charlottenburg

14609

Rochester

15216

Pittsburgh

23234

Arlöv

27402

Skivarp

27609

Raleigh

29445

Goose Creek

29464

Mt. Pleasant

30308

Atlanta

30342

Atlanta

30625

Hanover

32607

Gainesville

32626

Chiefland

32703

Apopka

32935

Melbourne

33409

West Palm Beach

33472

Boynton Beach

33770

Largo

34121

Kassel

41017

Crescent Springs

41136

Gothenburg

43235

Columbus

44304

Akron

44614

Canal Fulton

45005

Franklin

51162

Skene

60322

Frankfurt am Main

63071

Offenbach

67005

Arkansas City

67114

Newton

67205

Wichita

67207

Wichita

70112

New Orleans

71547

Nitchitoches

73326

Deggingen

75185

Uppsala

77074

Houston

78229

San Antonio

84088

West Jordan

84109

Salt Lake City

84121

Salt Lake City

85028

Phoenix

85104

Phoenix

85224

Chandler

85308

Glendale

88239

Wangen

90274

Rolling Hills Estates

90736

Umeå

97070

Würzburg

97205

Portland

98226

Bellingham

98801

Wenatchee

99362

Walla Walla

04357

Leipzig

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY